Erasca faces patent infringement and trade secret allegations from Revolution Medicines over ERAS-0015

Erasca, Inc.

RevMed alleges ERAS-0015 infringes U.S. Patent No. 12,409,225 and misappropriated trade secrets.
Erasca believes the allegations are without merit and will vigorously contest them.
Erasca also announced a conference call at 4:30pm ET today to discuss preliminary Phase 1 data for ERAS-0015.
No data results were disclosed in this filing; only the call schedule is provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.